Amgen's maridebart cafraglutide blocks the same receptor tirzepatide activates, still produces close to 20% weight loss, and does it from a monthly injection instead of a weekly one — an antibody-format peptide drug with a genuinely unresolved mechanism and a real tolerability problem.
Maritide
-
MariTide and the Antagonist Paradox